The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Open accessPublished version of a preprint
Abstract
Purpose: Liquid biopsy (LBx) for tumor profiling is increasingly used, but concerns remain regarding negative results. A lack of results may truly reflect tumor genomics, or it may be a false negative that would be clarified by tissue testing. A method of distinguishing between these scenarios could help clarify when follow-on tissue testing is valuable. Experimental Design: Here we evaluate circulating tumor DNA (ctDNA) tumor fraction (TF), a quantification of ctDNA in LBx samples, for utility in identifying true negative results. We assessed concordance between LBx and tissue-based results, stratified by ctDNA TF, in a real-world genomic dataset of paired samples across multiple disease types. We also evaluated the frequency of tissue results identifying driver alterations in patients with lung cancer after negative LBx in a real-world clinicogenomic database. Results: The positive percent agreement and negative predictive value between liquid and tissue samples for driver alterations increased from 63% and 66% for all samples to 98% and 97% in samples with ctDNA TF ≥1%. Among 505 patients with lung cancer with no targetable driver alterations found by LBx who had subsequent tissue-based profiling, 37% had a driver, all of which had ctDNA TF <1%. Conclusions: Patients with lung cancer with negative LBx and ctDNA TF ≥1% are unlikely to have a driver detected on confirmatory tissue testing; such informative negative results may benefit instead from prompt treatment initiation. Conversely, negative LBx with ctDNA TF <1% will commonly have a driver identified by follow-up tissue testing and should be prioritized for reflex testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to cohorts of adult patients, we find that when ctDNA TF ≥ 1%, ctDNA sequencing is more sensitive for detection of alterations compared with samples with TF<1%, a key factor when interpreting ctDNA results.25”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“F1LCDx also reports genomic signatures including ctDNA TF. TBx were analyzed using F1CDx as described previously (16, 17).”
MethodEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606
Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., Gossai, A., Frampton, G. M., Torres, A. Z., Lehnert, E. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.3241 · Cited by 549
Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., Clark, T., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0237802 · Cited by 516
Self-citationPersonalized genomic analyses for cancer mutation discovery and interpretation
Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D. R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7161 · Cited by 415
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx118 · Cited by 412
Cited by
Fusco, N., Venetis, K., Pepe, F., Shetty, O. A., Fariñas, S. C., Heeke, S., Burnier, J. V., Patton, S. J., Heitzer, E., Nigita, G., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100301 · Cited by 78
Self-citationBhave, M. A., Quintanilha, J. C. F., Tukachinsky, H., Li, G., Scott, T. A., Ross, J. S., Pasquina, L. W., Huang, R. S. P., McArthur, H. L., Levy, M. A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07376-w · Cited by 70
Self-citationLiquid biopsies across the cancer care continuum
Landon, B. V., Annapragada, A. V., Niknafs, N., Velculescu, V. E., & Anagnostou, V. (2025) · Nature Medicine · doi:10.1038/s41591-025-04093-9 · Cited by 64
Sweeney, C. J., Petry, R., Xu, C., Childress, M. A., He, J., Fabrizio, D. A., Gjoerup, O. V., Morley, S., Catlett, T. S., Assaf, Z. J. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1096 · Cited by 51
Self-citationBorgeaud, M., Olivier, T., Bar, J., Saw, S. P. L., Parikh, K., Banna, G. L., Vito, C. D., Feldman, J., Le, X., & Addeo, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70024 · Cited by 65
Metadata
- Authors
- Rolfo, C. D., Madison, R. W., Pasquina, L. W., Brown, D. W., Huang, Y., Hughes, J. D., Graf, R. P., Oxnard, G. R., & Husain, H.
- Affiliations
- Tisch Cancer Institute (US)
- Foundation Medicine (United States) (US)
- Boston Medical Center (US)
- Moores Cancer Center (US)
- Corresponding author
- Rolfo, Christian D.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2024-03-25
- Volume
- 30
- Issue
- 11
- Pages
- 2452-2460
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC11145175
- OpenAlex
- W4393144776
- Cited by
- 104
- References
- 30
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 12
- FWCI
- 20.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- International Association for the Study of Lung Cancer
- Lung Cancer Research Foundation
- Regeneron Pharmaceuticals
- Boston Pharmaceuticals
- Invitae
- EMD Serono
- Foundation Medicine
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- circulating tumor DNA, tumor fraction, liquid biopsy, false-negative results, driver alterations, lung cancer, reflex testing, cancer genomics
- MeSH terms
- Liquid Biopsy, Circulating Tumor DNA, Female, Humans, Lung Neoplasms, Mutation, Neoplasms, Biomarkers, Tumor, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3321
- The paper
- Rolfo, C. D., Madison, R. W., Pasquina, L. W., Brown, D. W., Huang, Y., Hughes, J. D., Graf, R. P., Oxnard, G. R., & Husain, H. (2024). Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.